News | June 25, 2025
Glenmark Pharmaceuticals launches TEVIMBRA in India
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The transaction is expected to close in Q2 FY 2026
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Globally, BRUKINSA is approved in more than 70 countries
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Annual EBITDA margin expands by 170 basis points
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Subscribe To Our Newsletter & Stay Updated
